NCT03830684Unknown2 期
A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase Ⅱa Clinical Trial for the Effectiveness and Safety of Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.0 个研究点目标入组 180 人开始时间: 2019年2月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 180
- 主要终点
- The time of fever relieving
研究概览
简要总结
This study in order to evaluate the Baicalein Tablets' safety and efficiency for audit with influenza
详细描述
This study in order to evaluate the Baicalein Tablets' safety and efficiency for audit with influenza, The trial designed by randomized, double-blind, placebo-controlled, multicenter and optimal efficiency. Subjects will be randomly assigned to low-dose group, high-dose group or placebo group as 1:1:1 proportionally, planned to enroll 180 subjects, each group enroll 60 subjects. The primary indicator is the time of fever relieving, comparison after the second visit. The secondary indicator are symptom alleviating time of influenza, percentage of subjects with influenza complications, percentage of antipyretic drugs used, percentage of virus positive to negative, comparison at the end of the experiment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1.Meet the diagnostic criteria for influenza（non-severe）; 2.Fever to take medicine for the first time, The patient's maximum temperature (axillary temperature) is over 38℃; 3.The rapid virus antigen test of nasal swab was positive; 4.Course of disease ≤ 24 hours(The definition of course of disease is the time from fever to take investigational product for the first time); 5.Aged 18 to 65 years old(include 18 and 65), all genders; 6.Sign the informed consent form.
排除标准
- •1.The patients with severe influenza or complication (e.g. secondary bacterial pneumonia, pneumonia caused by other pathogens or other viral pneumonia); 2.The patients with other acute upper respiratory tract infection (e.g. acute pharyngitis, tonsillitis, rhinitis and nasosinuitis); 3.Allergic to baicalin and its analogue, Paracetamol tablets, or allergic people; 4.Patients with any of the following risk factors:
- •Residents living in long-term care facilities (e.g. welfare house, sanatorium);
- •Combined with chronic respiratory diseases (e.g. bronchial asthma, chronic obstrctive palmonary diseases);
- •Combined with chronic cardiovascular disease (e.g. congenital heart disease, congestive heart failure, or coronary artery disease, but doesnt include hypertension without any other cardio-related symptoms);
- •Combined with hematological system diseases (e.g. chronic myelogenous leukemia, lymphocytic leukemia, myelodysplastic syndrome, aplastic anemia);
- •Neurodevelopmental disorders, include cerebrum, spinal cord, Peripheral nerve and muscle disorders (e.g. cerebral palsy, epilepsy[epileptic seizure disorder], stroke, dysgnosia, Moderate to severe dysplasia, myodystrophy, or spinal cord injury);
- •Poor control of chronic metabolic and endocrine diseases;
- •Immunosuppression (long-term use of immunosuppressant, immunocom promise caused by infection by HIV or malignant tumour);
- •Obese people[BMI>30, BMI=Weight(kg)/Height(m2)] 5.Long-term take aspirin under 19 years old; 6.White blood cell count>11.0×109/L, or the proportion of neutrophils >80%, or need systemic antibacterial therapy; 7.24 hours before the visit, the patients have received antiviral treatment for influenza; 8.The patients have received Influenza vaccine or research monoclonal antibody in a year; 9.ALT and AST is equal or greater than 1.5 times of upper limit of normal, Scr is greater than upper limit of normal; 10.Suspected or really have a history of alcohol or drug abuse; 11.Gestation (have a positive pregnancy test), lactating women, or have a family planning within the next 6 months; 12.The patients have participated in other clinical trials within 3 months; 13.The investigator considers it inappropriate to participate in this clinical trial.
研究组 & 干预措施
low-dose group
Experimental
Baicalein Tablets group
干预措施: Baicalein Tablets 400mg (Drug)
high-dose group
Experimental
Baicalein Tablets group
干预措施: Baicalein Tablets 600mg (Drug)
placebo group
Placebo Comparator
control group
干预措施: blank control 0mg (Drug)
结局指标
主要结局
The time of fever relieving
时间窗: day 3
After the first dose, the time of subjects' armpit temperature reduced to 37.3℃, and no longer increases in 24h.
次要结局
- symptom alleviating time of influenza(day 3 and day 5)
- Percentage of subjects with influenza complications Percentage of subjects with influenza complications(day 3 and day 5)
- Percentage of antipyretic drugs used(day 3 and day 5)
- Percentage of virus positive to negative(day 3 and day 5)
研究者
相似试验
已完成
3 期
A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic ArthritisJuvenile Idiopathic ArthritisNCT03773978Eli Lilly and Company220
已完成
不适用
Biatain Ibu vs. Biatain in Painful Chronic Venous Leg UlcersLeg UlcersNCT00627094Coloplast A/S120
已完成
1 期
Study to Investigate the Safety, Tolerability, Biological Effects and Preliminary Pharmacokinetics of Increasing Doses of BIIL 284 BS in Healthy Male VolunteersHealthyNCT02273414Boehringer Ingelheim35
已完成
3 期
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)Systemic Lupus ErythematosusNCT03616964Eli Lilly and Company778
终止
3 期
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT03616912Eli Lilly and Company830